Tvardi Therapeutics reported Phase 1 results for TTI-109, its next-generation STAT3 inhibitor, confirming the prodrug design and indicating improved tolerability versus its predecessor TTI-101. The update is incremental but supportive for the program’s development pathway, helping reduce early safety concerns relative to the prior compound.
Tvardi Therapeutics reported Phase 1 results for TTI-109, its next-generation STAT3 inhibitor, confirming the prodrug design and indicating improved tolerability versus its predecessor TTI-101. The update is incremental but supportive for the program’s development pathway, helping reduce early safety concerns relative to the prior compound.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
